GLPBio

JAK

Read More about this category

Janus kinases (JAKs), belonging to a distinct family of tyrosine kinases, are non-receptor tyrosine kinases that transduce signals of cytokine receptors via diverse signal transduction pathways. Mammalian JAK family consists of four structurally similar members, JAK1, JAK2, JAK3 and Tyrosine kinase 2 (TYK2), which are characterized by containing seven JAK homology (JH) domains. The presence of JH1 and JH2 domains is the most intriguing feature of JAK proteins. JH1 domain is the main catalytic domain; while JH2 is usually considered as a catalytically inactive pseudokinase domain. However, results of recent studies have shown that JH2 acts as a dual-specificity protein kinase to phosphorylate two regulatory sites (Ser523 and Tyr570) in JAK2.

Products Related to JAK(190)

  • GC14938 structure
    GC14938PF-03394197(Oclacitinib)
    CAS: 1208319-26-9
    Purity: >98.00%

    Novel Janus kinase inhibitor

  • GC15125 structure
    GC15125ZM 449829
    CAS: 4452-06-6
    Purity: >98.00%

    An inhibitor of JAK3

  • GC15589 structure
    GC15589WHI-P154
    CAS: 211555-04-3
    Purity: >99.00%

    A JAK3 inhibitor

  • GC15956 structure
    GC15956WHI-P97
    CAS: 211555-05-4
    Purity: >99.00%
  • GC15980 structure
    GC15980WP1066
    CAS: 857064-38-1
    Purity: >99.50%

    WP1066은 STAT3 (신호 전달자 및 전사 활성화 인자 3)의 가역적 경쟁 억제제로 STAT3 Tyr705 인산화를 억제하는 IC50이 약 2.5μM이다. WP1066은 악성 종양(교모세포종, 간세포암, 유방암 등)과 염증 관련 질환 연구에서 일반적으로 사용된다.

  • GC16124 structure
    GC16124Ruxolitinib phosphate
    CAS: 1092939-17-7
    Purity: >99.50%

    JAK1/JAK2의 강력하고 선택적인 억제제

  • GC16468 structure
    GC16468CYT387 sulfate salt
    CAS: 1056636-06-6
    Purity: >98.00%

    A potent inhibitor of JAK1 and JAK2

  • GC16828 structure
    GC16828Tofacitinib (CP-690550,Tasocitinib)
    CAS: 477600-75-2
    Purity: >98.00%

    Tofacitinib (CP-690550,Tasocitinib)은 류마티스 관절염, 류마티스 관절염, 강직성 척추염, 다관절형 유소년 특발성 관절염 그리고 궤양성 대장염 치료를 위한 Janus kinase(JAK) 저해제이다.

  • GC16875 structure
    GC16875FLLL32
    CAS: 1226895-15-3
    Purity: >99.50%

    커큐미나의 합성 유사체인 FLLL32는 항종양 활성이 있는 JAK2/STAT3 이중 억제제입니다. FLLL32는 유방암 세포에서 IFNα 및 IL-6에 의한 STAT3 인산화 유도를 억제할 수 있습니다.

  • GC17020 structure
    GC17020S-Ruxolitinib (INCB018424)
    CAS: 941685-37-6
    Purity: >99.50%
  • GC17050 structure
    GC17050CYT387
    CAS: 1056634-68-4
    Purity: >98.50%

    A potent inhibitor of JAK1 and JAK2

  • GC17055 structure
    GC170551,2,3,4,5,6-Hexabromocyclohexane
    CAS: 1837-91-8
    Purity: >98.00%

    Potently and directly inhibits JAK2 tyrosine kinase autophosphorylation, specifically inhibiting ligand-dependent JAK2 activation.

  • GC17222 structure
    GC17222GLPG0634 analogue
    CAS: 1206101-20-3
    Purity: >98.50%

    GLPG0634 유사체(화합물 176)는 JAK1, JAK2 및 JAK3에 대한 IC50 값이 100nM 미만인 광범위한 JAK 억제제입니다.

  • GC17586 structure
    GC17586Tofacitinib (CP-690550) Citrate
    CAS: 540737-29-9
    Purity: >99.50%

    A pan-JAK inhibitor

  • GC17762 structure
    GC17762NSC 33994
    CAS: 82058-16-0
    Purity: >98.00%

    Selective inhibitor of JAK2 (IC50 = 60 nM). Displays no effect on Src and TYK2 tyrosine kinase activity at a concentration of 25 μM.

  • GC19204 structure
    GC19204Itacitinib
    CAS: 1334298-90-6
    Purity: >99.50%

    Itacitinib은 JAK1 억제제(IC₅₀=2nM)이다. Itacitinib은 JAK1 티로신 키나아제를 선택적으로 억제해서 JAK-STAT 신호 전달 경로를 조절하고 동시에 전염증성 사이토카인 생성을 감소시켜 면역 반응을 조절한다.

  • GC19288 structure
    GC19288PF-06651600
    CAS: 1792180-81-4
    Purity: >99.50%

    PF-06651600(PF-06651600)은 IC50이 33.1nM인 경구 활성 및 선택적 JAK3 억제제입니다.

  • GC19320 structure
    GC19320SAR-20347
    CAS: 1450881-55-6
    Purity: >98.00%

    SAR-20347은 IC50이 각각 0.6, 23, 26 및 41nM인 TYK2, JAK1, JAK2 및 JAK3의 억제제입니다.

  • GC19334 structure
    GC19334Solcitinib
    CAS: 1206163-45-2
    Purity: >99.50%

    솔시티닙은 JAK2, JAK3 및 TYK2에 비해 IC50이 각각 9.8nM, 11배, 55배 및 23배인 경구 활성, 경쟁적, 강력한 선택적 JAK1 억제제입니다. 솔시티닙은 중등도에서 중증의 판형 건선 연구에 사용됩니다.

  • GC19368 structure
    GC19368Upadacitinib
    CAS: 1310726-60-3
    Purity: >98.00%

    Upadacitinib는 IC50 값이 0.043μM인 강력한 효능을 가진 경구 투여용 가역적이고 선택적인 Janus kinase 1(JAK1) 억제제이다.

  • GC19405 structure
    GC19405PF-06700841 P-Tosylate
    CAS: 2140301-96-6
    Purity: >99.50%

    PF-06700841 P-Tosylate는 강력한 이중 자누스 키나제 1(JAK1) 및 TYK2 억제제로 각각의 IC50 값은 17nM 및 23nM이다.

  • GC19408 structure
    GC19408FM381
    CAS: 2226521-65-7
    Purity: >98.00%

    FM-381 is a highly potent and JAK3-selective janus kinase (JAK) inhibitor

  • GC25168 structure
    GC25168Brepocitinib (PF-06700841)
    CAS: 1883299-62-4
    Purity: >98.00%

    Brepocitinib (PF-06700841, PF-841) is a potent inhibitor of Tyk2 and Jak1 with IC50s of 23 nM, 17 nM, 77 nM for Tyk2, Jak1 and Jak2 respectively. It has appropriate in-family selectivity against JAK2 and JAK3.

  • GC25869 structure
    GC25869RO495
    CAS: 1258296-60-4
    Purity: >98.00%

    RO495 (CS-2667) is a potent inhibitor of Non-receptor tyrosine-protein kinase 2 (TYK2).